Report top-line data from the Phase 2 trial
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 14 Sep 2022
- Due
- 31 Dec 2023
- Delivered
- February 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“with top-line data expected in 2H 2023”
What we found
Evidence strength A What the grades mean
The company reported preliminary data for a single cohort in May 2023, but the full top-line data for the completed Phase 2 dose exploration study was not reported until February 2024.
-
A Larimar Therapeutics, Inc. 10-K filed 2024-03-14
“In May 2023, we reported preliminary unblinded top-line data from the 25 mg cohort of our Phase 2 four-week, placebo-controlled, dose exploration trial” ✓ confirmed on the page
-
A Larimar Therapeutics, Inc. 10-K filed 2024-03-14
“In February 2024, we reported positive top-line data and successful completion of our four-week, placebo-controlled Phase 2 dose exploration study” ✓ confirmed on the page
Market reaction: the shares moved -9.9% against the S&P 500 over the three sessions around the disclosure (13 Mar 2024 to 18 Mar 2024). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +91 days
- 3 versions
-
Version 1 · original · stated 14 Sep 2022
Deadline 31 Dec 2023 (“in 2H 2023”) · wording expected
-
Version 2 · stated 25 Jul 2023
Deadline 30 Jun 2024 (“in 1H 2024”) · wording expected
“Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024”
-
Version 3 · stated 14 Nov 2023
Deadline 31 Mar 2024 (“in Q1 2024”) · wording expected
“Top-line safety, pharmacokinetic, and frataxin data from the Phase 2 trial now expected in Q1 2024”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- top-line data from Phase 2 trial
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Larimar Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-LRMR-002938 · Corrections policy